number of incontinence and micturition episodes/day. Analyses of covariance were used to assess the effects of mirabegron on baseline-week 12 changes in WPAI. Longitudinal generalized estimating equations and Pearson correlation coefficients were used to assess associations between WPAI and OAB severity. Subgroup analyses were conducted for patients who discontinued prior OAB medication due to insufficient efficacy. RESULTS: Among the study sample (total N=858, employed N=394), mirabegron-treated patients experienced significantly greater improvement in TAI (12.3% vs. 6.7%, p<0.01) and greater but nonsignificant improvements in absenteeism (0.2% vs.-0.5%), presenteeism (8.6% vs. 6.0%), and TWPI (8.2% vs. 5.8%) than placebo-treated patients at week 12.. Based on the association analyses, 2.0%, 1.4% and 1.4% increases per additional incontinence episode and, 1.2%, 1.1% and 1.1% increases per additional micturition episode were observed in TAI, presenteeism, and TWPI respectively (p<0.01). Baseline-week 12 change in TAI was significantly correlated with changes in OAB severity (incontinence: r=0.17, micturition: r=0.11; p<0.01). Similar trends were observed in the patient-subgroup with prior treatment nonresponse. CONCLUSIONS: Patients treated with mirabegron experience significantly reduced total activity impairment. Impairments in work productivity and activity outcomes are associated with OAB symptom severity, suggesting that treatments that improve symptom severity may also improve productivity impairment.
<div>Prøv at lytte godt efter næste gang, du tænder op i din brændeovn. Det, du sandsynligvis vil kunne høre, er din nabo, der hoster. Røgen fra brændeovnene er nemlig ved at forvandle rolige parcelhuskvarterer til områder, der er så plagede af luftforurening, at selv de mest befærdede veje i København har svært ved at følge med. Selvom der endnu ikke er sikkerhed om helbredseffekterne peger flere ting på, at røgen ikke er ufarlig – langt fra.</div>
A183by the patient preference to different characteristics of ESA treatments. Patients had to complete a questionnaire at baseline and around 6-month. Questionnaire was developed using a CBC analysis method with the following hypothesis: 1) 7 ESA characteristics; 2) from 2 to 3 levels per characteristics; 3) each possible answer includes 1 level for 2 characteristics; 4) 2 choices per question; 5) and 6) 7 questions per CBC questionnaire. The number of combinations between all characteristics and levels was 288, and 20 questionnaires have been generated in order to mix all possible treatment characteristics and levels. Patients only had to answer one questionnaire and a randomization has been used to obtain equal number of respondents for each questionnaire. CBC analysis was planned and performed for subgroup of patients already receiving ESA or not. RESULTS: A total of 790 patients were included, 609 questionnaires were analyzed at baseline. Fifty-five percent of patients were already treated by ESA, among them the most important characteristic was the planned frequency of administration for 31%, followed by the importance of the treatment efficacy for 20%, the pain at injection site for 11%. But when asking a direct question to patient on which characteristic was the most important, 82% of them answered treatment efficacy, 5% for pain at injection site and frequency of injection. Similar results were found for ESA naïve patients. CONCLUSIONS: The CBC analysis revealed that frequency of injections is underestimated by patients and should be taken into account by physicians when choosing an ESA treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.